The research, which comes from several groups including Genentech, makers of the prevailing anti-HER2 treatment, has researchers questioning ... By the late ’90s, a drug called Herceptin that targeted ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

The PD-1 checkpoint inhibitor cancer treatment is fast becoming the backbone ... biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised ...

They were pleading for “access - not excuses” when it came to Genentech’s promising new treatment for metastatic breast cancer: a drug called trastuzumab, also known as Herceptin®.

These patients should be given Herceptin drug for treatment. Health Secretary Patricia Hewitt has already ordered the National Institute for Health and Clinical Excellence (NICE), the drugs ...

The latest Herceptin biosimilar is branded as Kanjinti (trastuzumab-anns) and is approved in all indications of the reference product. These are for the treatment of HER2-overexpressing adjuvant ...

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

In the small group of study patients at M.D. Anderson who received Herceptin, says Buzdar, none so far has developed any heart problems almost two years after treatment. Some doctors have ...

Herceptin was the most obvious candidate to establish proof of concept—especially for the part of the treatment where it is administered as monotherapy, Schmidt adds. “That is mainly the case ...

Hence she and her family had to start a fundraising campaign to pay for her treatment privately. She has now started a year-long course of Herceptin at the Christie Hospital in Manchester.

Herceptin is one of a new class of drugs called monoclonal antibodies -- lab-engineered antibodies designed to mimic the body's own immune system response. Herceptin targets the HER2 protein ...